BiotechTube

BMS-931699 + BMS-986142 + Placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sjögren's Syndrome

Conditions

Sjögren's Syndrome

Trial Timeline

Oct 18, 2016 → Jul 24, 2017

NCT ID
NCT02843659

About BMS-931699 + BMS-986142 + Placebo

BMS-931699 + BMS-986142 + Placebo is a phase 2 stage product being developed by Bristol Myers Squibb for Sjögren's Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT02843659. Target conditions include Sjögren's Syndrome.

What happened to similar drugs?

0 of 8 similar drugs in Sjögren's Syndrome were approved

Approved (0) Terminated (1) Active (7)
❌KCT-0809 ophthalmic solutionKissei PharmaceuticalPhase 3
🔄KCT-0809 ophthalmic solution + PlaceboKissei PharmaceuticalPhase 3
🔄KCT-0809 ophthalmic solutionKissei PharmaceuticalPhase 3
🔄DazodalibepAmgenPhase 3
🔄Dazodalibep + PlaceboAmgenPhase 3
🔄DeucravacitinibBristol Myers SquibbPhase 3
🔄Abatacept SCBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02843659Phase 2Terminated

Competing Products

20 competing products in Sjögren's Syndrome

See all competitors
ProductCompanyStageHype Score
LY3090106 + PlaceboEli LillyPhase 1
29
VAY736 + PlaceboNovartisPhase 2
35
CDZ173 + PlaceboNovartisPhase 2
35
VAY736 lower dose + VAY736 higher doseNovartisPhase 1/2
24
CFZ533 active - Cohort 1 + CFZ533 placebo- Cohort 1 + CFZ533 active - Cohort 2 + CFZ533 placebo - Cohort 2 + CFZ533 active -Cohort 3 + CFZ533 active - Cohort 3NovartisPhase 2
35
Rapcabtagene autoleucelNovartisPhase 1/2
39
KCT-0809 ophthalmic solutionKissei PharmaceuticalPhase 3
32
KCT-0809 ophthalmic solution + PlaceboKissei PharmaceuticalPhase 3
40
KCT-0809 ophthalmic solutionKissei PharmaceuticalPhase 3
40
DazodalibepAmgenPhase 3
47
VIB4920 + PlaceboAmgenPhase 2
35
AMG 557/MEDI5872AmgenPhase 2
35
Dazodalibep + PlaceboAmgenPhase 3
44
IBI355 + IBI355 placeboInnovent BiologicsPhase 1
29
DeucravacitinibBristol Myers SquibbPhase 3
44
Abatacept SCBristol Myers SquibbPhase 3
40
SAR441344 + PlaceboSanofiPhase 2
35
Hydroxychloroquine + PlaceboSanofiPhase 3
40
UCB5857 + PlaceboUCBPhase 2
27
Efgartigimod + PlaceboArgenxPhase 2
32